GE Healthcare Korea said Monday that it has launched Clariscan, a new macrocyclic MRI contrast agent, in Korea.
Clariscan is a gadolinium-based contrast agent (GBCA) designed to support effective visualization of abnormalities in the brain, spine and associated tissues.
According to the company, the agent is known to be a gold-standard detection tool in MR imaging, offering an improved contrast between normal and pathological tissue to enable rapid detection of abnormalities.
“As the value of sustainable medical services is increasingly prominent along with rapid procedural advancements in MRI, there is a growing focus on advancing precision medicine in the healthcare market,” GE Healthcare Korea CEO Francis Van Parys said. “We believe Clariscan provides additional options for radiology professionals, backed by the well-established quality, reliability and surrounding services GE customers have come to expect.”
GE Healthcare invested over $65 million in its worldwide supply network between 2013 and 2016 to increase manufacturing capacity for imaging and contrast agent business. The company’s product is used in more than 70 million procedures a year.
<© Korea Biomedical Review, All rights reserved.>